What Is Urolithin A?
Urolithin A (UA) is a metabolite produced when gut bacteria transform ellagitannins and ellagic acid — polyphenols found in pomegranates, walnuts, raspberries, and strawberries. You don't consume urolithin A directly from food; instead, specific gut microbes convert dietary polyphenols into this bioactive compound during digestion.
This gut-dependent production creates a significant problem: not everyone can make urolithin A. Studies estimate that only 30–40% of the population harbors the right gut microbial composition to efficiently convert ellagitannins to urolithin A. The rest produce little or none, regardless of how many pomegranates they eat. This variability is one of the key reasons urolithin A has been developed as a direct supplement — bypassing the gut microbiome bottleneck entirely.
The commercial form, branded as Mitopure® by the Swiss company Timeline (formerly Amazentis), has been the subject of a systematic clinical research program spanning multiple Phase 1 and Phase 2 trials. This level of structured clinical development is unusual for a supplement ingredient and lends credibility to the evidence base.
How Urolithin A Works
Mitophagy Activation
Urolithin A's primary mechanism is the activation of mitophagy — a specialized form of autophagy that selectively targets and recycles damaged or dysfunctional mitochondria. Mitochondria are the cellular powerhouses responsible for producing ATP (energy), but they also generate reactive oxygen species as a byproduct. Over time, accumulated mitochondrial damage contributes to cellular dysfunction and aging.
Healthy cells continuously perform quality control on their mitochondrial population: damaged units are tagged, engulfed, and broken down, with their components recycled to build new, functional mitochondria. This quality control process declines with age, leading to an accumulation of dysfunctional mitochondria — a hallmark of aging recognized across multiple organ systems.
Urolithin A activates mitophagy through several overlapping pathways:
- PINK1/Parkin pathway. UA stabilizes PINK1 (PTEN-induced kinase 1) on the surface of damaged mitochondria, recruiting the E3 ubiquitin ligase Parkin and initiating the mitophagy cascade.
- AMPK activation. UA activates AMP-activated protein kinase, the master energy sensor that promotes catabolic and quality control processes including mitophagy.
- SIRT1 activation. UA has been shown to activate sirtuin 1, a deacetylase enzyme that coordinates mitochondrial biogenesis and quality control.
The net effect is a cleaner, more functional mitochondrial pool — which translates to better cellular energy production, reduced oxidative stress, and improved tissue function.
Mitochondrial Biogenesis
Beyond removing damaged mitochondria, urolithin A also stimulates the production of new ones. This dual action — clearing out the old and building the new — results in a net improvement in mitochondrial quality and quantity. Markers of mitochondrial biogenesis, including PGC-1α expression and mitochondrial DNA copy number, increase with UA exposure in both preclinical and clinical studies.
Muscle-Specific Effects
Skeletal muscle is one of the most mitochondria-dense tissues in the body, and mitochondrial dysfunction is a primary driver of age-related muscle decline (sarcopenia). Urolithin A's effects are particularly relevant to muscle because:
- Improved mitochondrial function directly enhances muscle energy production and endurance capacity
- Better mitochondrial quality reduces intramuscular oxidative stress and inflammation
- Enhanced mitophagy supports the regenerative capacity of muscle stem cells (satellite cells)
These muscle-specific mechanisms explain why clinical trials have focused on exercise endurance and physical function as primary outcomes.
Anti-Inflammatory Effects
Urolithin A has demonstrated anti-inflammatory properties in multiple preclinical models, reducing NF-κB activation, IL-6, TNF-α, and other inflammatory mediators. Chronic inflammation ("inflammaging") is both a cause and consequence of mitochondrial dysfunction, creating a vicious cycle that UA may help interrupt.
Urolithin A Benefits: Clinical Trial Evidence
Andreux 2019 — First-in-Human Trial (Nature Metabolism)
The first rigorous human study of urolithin A was published by Andreux et al. in Nature Metabolism [1]. This randomized, double-blind, placebo-controlled trial enrolled 60 sedentary older adults and tested three doses of urolithin A (250 mg, 500 mg, and 1000 mg) against placebo over 4 weeks.
Key findings:
- Mitochondrial biomarkers. UA supplementation (500 mg and 1000 mg) significantly improved plasma acylcarnitine profiles, indicating enhanced mitochondrial fatty acid oxidation.
- Gene expression. Muscle biopsies revealed upregulation of mitochondrial genes and mitophagy-related pathways.
- Safety. All doses were well tolerated with no serious adverse events.
- Dose response. The 500 mg and 1000 mg doses were most effective, establishing the clinical dose range.
This trial provided the mechanistic confirmation that oral urolithin A supplementation activates mitophagy in human muscle tissue — not just in cell cultures or animal models.
Liu 2022 — Muscle Endurance RCT (JAMA Network Open)
The most impactful clinical trial was published by Liu et al. in JAMA Network Open [2]. This randomized, double-blind, placebo-controlled study enrolled 66 adults aged 65–90 and assigned them to 1000 mg urolithin A or placebo daily for 4 months.
Key findings:
- Muscle endurance. The UA group showed significantly improved muscle endurance in both hand grip and leg exercise tests compared to placebo. The improvement in 6-minute walk distance was clinically meaningful.
- Plasma biomarkers. UA supplementation reduced plasma acylcarnitines (C2, C4) and ceramides — biomarkers associated with mitochondrial dysfunction and metabolic risk.
- Inflammatory markers. CRP (C-reactive protein) levels decreased in the UA group, suggesting systemic anti-inflammatory effects.
- No change in muscle mass. Importantly, UA improved muscle *function* without significantly increasing muscle *mass*, suggesting the benefit is primarily through improved mitochondrial quality rather than hypertrophy.
This JAMA trial is particularly significant because it used a hard functional outcome (exercise performance) rather than just biomarkers, and it was published in one of the most rigorous medical journals — lending substantial credibility.
Singh 2022 — Biomarker Study (Cell Reports Medicine)
Singh et al. published a detailed biomarker analysis in Cell Reports Medicine, examining the molecular signature of urolithin A supplementation in humans [3]. This study extended the mechanistic understanding by showing:
- Reduction in plasma inflammatory cytokines (IL-6, TNF-α)
- Improvement in mitochondrial respiration markers in peripheral blood mononuclear cells (PBMCs)
- Correlation between urolithin A plasma levels and the degree of mitochondrial biomarker improvement
The PBMC data is noteworthy because it suggests systemic mitochondrial benefits beyond skeletal muscle — affecting immune cells and potentially other tissues.
Additional Supporting Evidence
- Preclinical lifespan studies. Urolithin A extended lifespan in C. elegans (roundworms) and improved healthspan metrics in aged mice, including exercise capacity and cognitive function.
- Neuroprotection. Animal studies show that UA reduces neuroinflammation and improves cognitive function in Alzheimer's disease models, though human cognitive trials are still underway.
- Joint health. A pilot study suggested UA may reduce cartilage degradation biomarkers, opening potential applications in osteoarthritis.
Dosage and How to Take Urolithin A
The clinically studied dose range is 500–1000 mg per day, with 1000 mg used in the most robust trials.
Commercial products:
- Mitopure® (Timeline): The most researched form, available as softgels (500 mg or 1000 mg), powder sachets, and protein powder. This is the exact form used in the published clinical trials.
- Generic urolithin A: Some supplement companies now offer urolithin A at varying doses and purity levels. Quality may vary since these haven't been independently tested in clinical trials.
Timing: Clinical trials administered urolithin A in the morning with breakfast. It's fat-soluble and likely better absorbed with a meal containing dietary fat.
Duration: The Andreux trial showed biomarker changes within 4 weeks, while the Liu trial demonstrated functional improvements over 4 months. A minimum of 2–4 months of consistent use is reasonable to expect meaningful benefits.
Who might not need supplementation:
If you're among the 30–40% of people who efficiently convert dietary ellagitannins to urolithin A (sometimes called "UA producers"), you may already achieve adequate levels through diet. A urolithin A blood test (offered by some companies) can determine your producer status, though the clinical utility of this testing is not yet established.
Safety and Side Effects
Urolithin A has a strong safety profile across published clinical data:
- FDA GRAS status has been granted for urolithin A
- Doses up to 2000 mg/day have been tested in safety studies without concerning findings
- The Liu 2022 JAMA trial reported no significant difference in adverse events between UA and placebo groups over 4 months [2]
- No drug interactions have been reported in clinical studies
- Long-term safety data beyond 4 months is not yet available from published trials
Mild reported side effects:
- Occasional gastrointestinal discomfort (mild nausea, loose stools) in a small percentage of participants
- Headache (reported at similar rates in UA and placebo groups)
Who should exercise caution:
- Pregnant or breastfeeding women (insufficient safety data)
- Individuals on anticoagulant therapy (theoretical interaction due to polyphenol origin, though not observed clinically)
- Those with severe renal impairment (urolithin A is renally excreted; reduced clearance may alter exposure)
How Urolithin A Compares to Other Mitochondrial Supplements
The mitochondrial health supplement space includes several notable compounds. Here's how urolithin A stacks up:
CoQ10: Well-established as a mitochondrial electron transport chain cofactor. Strong evidence for heart failure patients and statin users. However, CoQ10 supports existing mitochondrial function rather than clearing damaged mitochondria — a fundamentally different mechanism from UA's mitophagy activation.
PQQ (Pyrroloquinoline quinone): Promoted for mitochondrial biogenesis. Evidence is primarily preclinical, with human trials showing modest effects on inflammation markers but not clear functional outcomes. Urolithin A has significantly stronger clinical evidence.
NMN and NR (NAD+ precursors): These boost NAD+ levels, which supports mitochondrial function through sirtuin activation. The evidence base is growing but mixed — some trials show biomarker changes without corresponding functional improvements. Urolithin A's mitophagy mechanism is complementary and has demonstrated functional outcomes (muscle endurance) that NMN/NR trials have not yet matched.
Resveratrol: An AMPK/sirtuin activator with decades of preclinical promise but disappointing clinical translation. Poor bioavailability and rapid metabolism limit its effectiveness. Urolithin A has better pharmacokinetic properties and stronger clinical evidence.
Urolithin A's key advantage is its specificity: it directly activates the mitophagy pathway, which is the body's own mechanism for mitochondrial quality control. This targeted approach, combined with actual clinical trial evidence of functional improvement, sets it apart.
Limitations and Honest Assessment
What's strong:
- Multiple published RCTs, including one in JAMA Network Open
- Clear and well-characterized molecular mechanism (mitophagy via PINK1/Parkin)
- Functional outcomes (muscle endurance) demonstrated, not just biomarkers
- Strong safety profile with FDA GRAS status
- Systematic clinical development program unusual for a supplement
What's limited:
- Largest trial enrolled only 66 participants — larger trials are needed
- Longest published trial duration is 4 months — long-term effects unknown
- Most research has been funded by Timeline/Amazentis (the manufacturer)
- Effects on hard clinical endpoints (mortality, disease incidence) have not been studied
- Benefits in younger, healthier populations are less clear
- Cost is substantial (~$60–90/month for the clinically tested product)
The Verdict
Urolithin A has one of the strongest emerging evidence bases in the longevity supplement space. The combination of a clear molecular mechanism (mitophagy activation), multiple clinical trials with functional outcomes, publication in top-tier journals (Nature Metabolism, JAMA Network Open, Cell Reports Medicine), and a structured development program sets it apart from most supplement ingredients.
The JAMA Network Open trial showing improved muscle endurance in older adults is particularly compelling because it demonstrates a benefit people can actually feel — not just a change in a blood test. This is the kind of evidence that moves a compound from "biochemically interesting" to "potentially useful."
That said, the field is still maturing. Larger trials, longer follow-up, independent replication, and data on hard clinical endpoints are all needed. The cost is significant, and younger, healthy individuals may not derive the same magnitude of benefit as the sedentary older adults studied in trials.
Who might benefit most:
- Adults over 50, particularly those noticing age-related declines in energy or exercise capacity
- Sedentary individuals looking to improve mitochondrial health as a foundation for increased activity
- People interested in evidence-based longevity interventions with demonstrated functional outcomes
- "Non-producers" who cannot efficiently convert dietary polyphenols to urolithin A
Who might wait:
- Young, active, healthy individuals (the benefit–cost ratio is less clear)
- Those on tight budgets (more affordable mitochondrial support options like CoQ10 have longer track records)
- People who prefer to wait for independent replication and longer-term data
Urolithin A represents the kind of supplement that the longevity field needs more of: one backed by real clinical trials, a clear mechanism, and honest communication about what it can and can't do.